Navigation Links
Pharmatek Granted Approval by the DEA for Analysis of All Controlled Substances
Date:4/17/2011

SAN DIEGO, April 17, 2011 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has been approved by the United States Drug Enforcement Agency (DEA) for the analysis of Schedules I through V controlled substances, complementing its existing license to develop and manufacture drug products containing Schedules IV and V controlled substances.

"Receipt of this additional registration from the DEA demonstrates that we meet the Agency's stringent requirements, and further validates our facility design, security systems, and procedures for analysis, handling, storage and disposal of controlled substances," said Jeffrey Bibbs, Ph.D, CEO and CSO at Pharmatek.  "This registration allows us to perform analytical and stability testing for all controlled-substance drug products within both our non-potent and highly-potent GMP facilities."

Controlled substances are designated as Schedule I-V according to their medical use, potential for abuse and safety or dependence liability.  In order to research, manufacture or distribute a controlled substance, a person or entity must be audited and registered by the DEA.

"The DEA registration is another example of our efforts for continuous improvement and expansion of Pharmatek's services," said Timothy Scott, President at Pharmatek.  "As a client-centric organization, our success is predicated on our ability to serve our clients' evolving needs.  We are happy to bring this additional capability to Pharmatek in order to serve that purpose."

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry.  Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development and manufacturing.

Statements contained in this media release which are not historical facts may constitute forward-looking statements.  All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion.  The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc.  Additional information about Pharmatek Laboratories may be obtained at the Web site http://www.pharmatek.com or by calling 858-805-6383.

Company Contact:
Ryan Lane, Marketing Associate
Pharmatek Laboratories, Inc.
(858) 805-6383 x284
rlane@pharmatek.com


'/>"/>
SOURCE Pharmatek Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatek Laboratories Expands GMP Manufacturing Capabilities
2. Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast
3. Pharmateks Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds
4. Exergen Granted New Patent for Temporal Artery Thermometers
5. CardioGenics Granted Patent for Core Technology of its QL Care™ Analyzer
6. Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
7. Ascension Orthopedics Granted Patent for PyroCarbon Humeral Head Design
8. Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection
9. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
10. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
11. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 6, 2017  Diplomat Specialty Infusion Group, a brand ... environment to its Iowa location. ... now features an ISO 7 cleanroom—the standard needed to ... with a low level of pollutants. ... nutrition consumers and better serve our Iowa ...
(Date:6/2/2017)... June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading ... announced new findings demonstrating positive biochemical outcomes related to ... One™. The data will be presented at the ERA-EDTA ... Madrid, Spain . The research ... Dialysis Network in Europe ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference ... to read it, and some people don't like it at all. FindaTopDoc took a ... found: , Erotic literature can give readers a taste of their deepest, darkest fantasies ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently ... Talei has come up with a proprietary technique that he calls the AuraLyft ... have dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Breast Cancer Conference from Sept. 18 to 20. , The two-day conference is ... subtype with the goal of improving patients’ lives and eliminating racial breast cancer-related ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... MD Now’s 28th facility overall and marks the urgent care center's eighth location in ... North of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update of flood ... States. In 2012, the Biggert-Waters Act was enacted to reflect the actual risk ...
Breaking Medicine News(10 mins):